BUSINESS WIRE
-- Six Abstracts for Presentations and Posters Published on ARVO
Website --
JERSEY CITY, N.J.--(BUSINESS WIRE)--Lux Biosciences, Inc., a privately held biotechnology company
specialized in the field of ophthalmic diseases, announced today the
online publication of abstracts for presentations by the company and its
collaborators concerning the development of the company’s
lead phase 3 products LX211 and LX201, as well as two earlier stage
projects. The presentations will be part of the upcoming ARVO 2008
Annual Meeting, “Eyes on Innovation,”
to be held April 27 – May 1, 2008 in Fort
Lauderdale, FL. Access to the published abstracts is available on the
ARVO website at http://www.arvo.org.
“We will be showcasing at ARVO the depth of
Lux Biosciences’ development pipeline, and we
are very pleased to report remarkable progress with all of our projects,”
said Ulrich Grau, Ph.D., Lux Biosciences President and Chief Executive
Officer. “Notably, during this meeting we
have presentations on our two phase 3 clinical programs in uveitis and
in cornea transplantation. We also will be presenting highly original
work with bioerodible polymers as well as a clear, mixed micellar
formulation for ocular delivery of our next generation calcineurin
inhibitor (LX212 and LX214, respectively). These latter two product
candidates are tailor-made for dry eye and other, highly prevalent
chronic inflammatory diseases of the eye.”
|
Lux Biosciences’ presentations include
two orally presented papers:
|
|
|
|
Program Number:
|
|
1146
|
|
Abstract Title:
|
|
Design of Phase 2/3 Clinical Trials of a Cyclosporine A Eluting
Implant, LX201, for the Prevention and Treatment of Corneal
Allograft Rejection or Graft Failure in Patients at High Risk
|
|
Session Number:
|
|
210
|
|
Session Date/Start Time:
|
|
Monday Apr 28, 2008, 8:30 AM – 10:15 AM
|
|
Presentation Start-End Time:
|
|
8:30:00 AM – 8:45:00 AM
|
|
Room:
|
|
Floridian Ballroom BCD
|
|
|
|
|
|
Program Number:
|
|
5007
|
|
Abstract Title:
|
|
Development of a Bioerodible Insert for the Ocular Delivery of a
Novel Next Generation Calcineurin Inhibitor
|
|
Session Number:
|
|
501
|
|
Session Date/Start Time:
|
|
Thursday May 1, 2008, 8:30 AM – 10:15 AM
|
|
Presentation Start-End:
|
|
9:30:00 AM – 9:45:00 AM
|
|
Room:
|
|
Room 114
|
|
|
|
|
|
Four poster presentations relating to LX 211, LX201 and LX214 will
also be included as part of the ARVO meeting program:
|
|
|
|
Program Number:
|
|
114
|
|
Abstract Title:
|
|
Development and Characterization of a Clear, Mixed Micellar
Formulation of a Next-Generation Calcineurin Inhibitor, for
Treatment of Dry Eye Syndrome
|
|
Session Number:
|
|
106
|
|
Session Date/Start Time:
|
|
Sunday Apr 27, 2008, 8:30 AM – 10:15 AM
|
|
Poster Board:
|
|
A141
|
|
Room:
|
|
Hall B/C
|
|
|
|
|
|
Program Number:
|
|
1964
|
|
Abstract Title:
|
|
Preclinical Acute Toxicity and Pharmacokinetics of Episcleral
LX201 Implants in Rabbits
|
|
Session Number:
|
|
257
|
|
Session Date/Start Time:
|
|
Monday Apr 28, 2008, 11:15 AM – 1:00 PM
|
|
Poster Board:
|
|
D935
|
|
Room:
|
|
Hall B/C
|
|
|
|
|
|
Program Number:
|
|
3883
|
|
Abstract Title:
|
|
Design of Phase 2/3 Clinical Trials of a Novel Calcineurin
Inhibitor, LX211, for the Treatment of Non-Infectious Uveitis
|
|
Session Number:
|
|
418
|
|
Session Date/Start Time:
|
|
Wednesday Apr 30, 2008, 8:30 AM – 10:15 AM
|
|
Poster Board:
|
|
A503
|
|
Room:
|
|
Hall B/C
|
|
|
|
|
|
Program Number:
|
|
4745
|
|
Abstract Title:
|
|
LX211 (ISA247) Suppresses Anti-CD3 Activated Human T-Cell
Proliferation and Effectively Treats Experimental Autoimmune Uveitis
in Rats
|
|
Session Number:
|
|
479
|
|
Session Date/Start Time:
|
|
Wednesday Apr 30, 2008, 3:00 PM – 4:45 PM
|
|
Poster Board:
|
|
A551
|
|
Room:
|
|
Hall B/C
|
About Lux Biosciences
Lux Biosciences, Inc. is a privately held biotechnology company focused
on ophthalmic diseases. The company has a staged product portfolio of
potentially first-in-class therapies distinguished by their short-term
path to commercialization and potential to generate high revenue growth.
The portfolio includes:
-
Two Phase III clinical-stage projects including: i) LX211, the oral
formulation of a next-generation calcineurin inhibitor developed as
steroid sparing therapy for the treatment of non-infectious uveitis,
and ii) LX201, a silicone matrix ocular (episcleral) implant that
steadily releases therapeutic doses of cyclosporine A locally to the
eye for the prevention of rejection cornea transplant recipients. Both
the LUMINATE pivotal clinical program for LX211 for the treatment of
uveitis, as well as the LUCIDA pivotal clinical program with LX201 for
the prevention of corneal transplant rejection were initiated in early
2007 and include sites in North America and Europe.
-
LX214, a novel topical eye drop formulation currently in IND-enabling
studies with a target date for entry into the clinic in mid 2008.
LX214 is based on Lux’ proprietary
next-generation calcineurin inhibitor and is targeted towards other
chronic inflammatory diseases of the eye, most notably dry eye
syndrome, blepharitis and atopic keratoconjunctivitis.
-
Several earlier stage projects based on proprietary product-enabling
bio-erodible polymer technologies that facilitate targeted and
sustained delivery of molecules to the eye.
For more information on Lux Biosciences, please visit the company’s
website at http://www.luxbio.com.